| Lee, Seung-Hwan |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes |
|
|
| Recruiting | 2 | 144 | RoW | PG-102, Placebo | ProGen. Co., Ltd. | Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus | 03/25 | 06/25 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT06155487: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects |
|
|
| Enrolling by invitation | 1 | 68 | RoW | AJH-2947 100 mg (SAD), Placebo, AJH-2947 200 mg (SAD), AJH-2947 300 mg (SAD), AJH-2947 400 mg (SAD), AJH-2947 600 mg (SAD), AJH-2947 800 mg (SAD), AJH-2947 200 mg (MAD), AJH-2947 400 mg (MAD), AJH-2947 600 mg (MAD) | JMackem Co., Ltd, Seoul National University Hospital | Neuropathic Pain, Diabetic Neuropathies, Post Herpetic Neuralgia | 04/25 | 09/25 | | |
NCT03611725: Comparison of Success Rate Between Distal Radial Approach and Radial Approach in STEMI |
|
|
| Completed | N/A | 352 | RoW | Distal radial artery, Radial artery | Wonju Severance Christian Hospital, Hanmi Pharmaceutical co., ltd. | Distal Radial Artery Approach, ST Elevation Myocardial Infarction | 03/23 | 12/23 | | |
| Recruiting | N/A | 5000 | RoW | | Yonsei University, Gangwon Cardiovascular Health Research Institute | Coronary Artery Disease | 12/30 | 12/31 | | |
| Mayer, Frank |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Kim, Moo-Hyun |
| Active, not recruiting | 4 | 2018 | RoW | Tailored antithrombotic strategy, Conventional antithrombotic strategy | Duk-Woo Park, MD, CardioVascular Research Foundation, Korea | Coronary Stenoses | 01/25 | 01/25 | | |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
| Recruiting | N/A | 4500 | RoW | Onyx Drug Eluting Stent group | Seung-Jung Park, CardioVascular Research Foundation, Korea, Medtronic Korea Co., Ltd. | Coronary Artery Disease, Arterial Occlusive Diseases, Cardiovascular Diseases, Percutaneous Transluminal Angioplasty | 12/25 | 12/29 | | |
| Recruiting | N/A | 1500 | RoW | Balloon angioplasty | Seung-Jung Park, CardioVascular Research Foundation, Korea, B. Braun Korea Co., Ltd. | Coronary Artery Disease, Angioplasty, Balloon | 12/24 | 06/28 | | |
| Chang, Kiyuk |
| Recruiting | 4 | 3548 | RoW | Ezetimibe 10mg + Rosuvastatin 5mg, Rosuzet 10/5 mg, Rosuvastatin 20mg, Crestor 20mg | Kiyuk Chang, MD,PhD | Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity | 08/26 | 08/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | N/A | 2186 | RoW | 1 Month vs. 12 Months DAPT | Kiyuk Chang, Uijeongbu St. Mary Hospital, St Vincent's Hospital, Bucheon St. Mary's Hospital, Wonju Severance Christian Hospital, Chungbuk National University Hospital, Daejeon St. Mary's hospital, Korea University Guro Hospital, Seoul St. Mary's Hospital | Coronary Artery Disease | 12/23 | 12/25 | | |
RECORD-AMI, NCT05770687: SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study |
|
|
| Recruiting | N/A | 1000 | RoW | SGLT2 inhibitor, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin | Kiyuk Chang, Seoul St. Mary's Hospital, Uijeongbu St. Mary Hospital, Incheon St.Mary's Hospital, Daejeon St. Mary's hospital, Bucheon St. Mary's Hospital, St Vincent's Hospital, Yeouido St. Mary's Hospital, Sejong General Hospital, Pusan National University Hospital, Andong Hospital, Chungnam National University Hospital, St. Carollo General Hospital, Pusan National University Yangsan Hospital, Kyungpook National University Hospital, Jeju National University Hospital, Korea University Anam Hospital, Inje University | Myocardial Infarction, Diabetes Mellitus, Type 2 | 12/25 | 12/26 | | |
| yoon, kun ho |
NCT03641352: The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes |
|
|
| Recruiting | 3 | 240 | RoW | CKD-501 0.5mg, Lobeglitazone, Placebo | Chong Kun Dang Pharmaceutical | Type2 Diabetes | 04/21 | 11/22 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
| GROSJEAN, JESSICA |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
QISEIN, NCT05241405: Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer |
|
|
| Recruiting | N/A | 354 | Europe | QISENG, PLACEBO | Centre Francois Baclesse, NATSUCA laboratory, Groupement Interrégional de Recherche Clinique et d'Innovation | Breast Cancer, Fatigue | 09/27 | 09/27 | | |
| Lee, Ji Hyun |
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age |
|
|
| Recruiting | 4 | 50 | RoW | rMenB+OMV NZ | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Meningitis, Meningococcal | 04/26 | 09/26 | | |
| Active, not recruiting | 3 | 878 | RoW | taxane plus carboplatin, Taxane | Yonsei University | Breast Cancer | 06/25 | 06/25 | | |
NCT05936658: [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer |
|
|
| Recruiting | 3 | 89 | RoW | [F-18]Florastamin | FutureChem | High Risk Prostate Carcinoma | 12/24 | 12/24 | | |
NCT05004285: Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis |
|
|
| Recruiting | 3 | 398 | RoW | [F-18]Florastamin | FutureChem | High Risk Prostate Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo | Chimerix | H3 K27M, Glioma | 08/26 | 08/26 | | |
|
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NCT05445128: Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease |
|
|
| Terminated | 2 | 1 | US | MGTA-145, Plerixafor | Ensoma, bluebird bio | Sickle Cell Disease | 12/22 | 02/23 | | |
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis |
|
|
| Completed | 2 | 116 | RoW | SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05% | SCAI Therapeutics | Dry Eye Syndromes | 08/23 | 02/24 | | |
NCT05819658: GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) |
|
|
| Completed | 2 | 78 | RoW | GV1001 Placebo, Normal saline, GV1001 0.56mg, Tertomotide 0.84mg, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael | Progressive Supranuclear Palsy | 10/24 | 10/24 | | |
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type |
|
|
| Active, not recruiting | 2 | 23 | RoW | IMC-001, Not confirm yet | ImmuneOncia Therapeutics Inc. | Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma | 07/24 | 02/26 | | |
LUCIDA_2, NCT05579184: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 |
|
|
| Active, not recruiting | 2 | 20 | RoW | [177Lu]Ludotadipep | FutureChem | Metastatic Castration-resistant Prostate Cancer, mCRPC | 12/24 | 12/24 | | |
| Recruiting | 2 | 34 | RoW | Busulfan, Busulfex, Fludarabine | Keimyung University Dongsan Medical Center, Otsuka Pharmaceutical Co., Ltd. | T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell | 12/25 | 12/27 | | |
NCT05599880: The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 29 | RoW | Bortezomib | Seoul National University Hospital | Relapsed/Refractory Immune Thrombocytopenia | 05/26 | 12/27 | | |
| Recruiting | 1/2 | 220 | Europe, Canada, US, RoW | BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation) | Bold Therapeutics, Inc., Bold Therapeutics, Inc. (Bold) | Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma | 06/26 | 09/26 | | |
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 400 | Europe, US, RoW | Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Cancer, Metastatic Breast Cancer | 12/24 | 08/26 | | |
NCT06521567: A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer |
|
|
| Recruiting | 1/2 | 95 | US | Cobolimab, Dostarlimab | GlaxoSmithKline | Melanoma | 08/28 | 11/30 | | |
NCT04306224: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas |
|
|
| Completed | 1 | 12 | US, RoW | IMC-002 | ImmuneOncia Therapeutics Inc. | Solid Tumor, Lymphoma | 10/22 | 10/22 | | |
NCT05276310: A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy |
|
|
| Recruiting | 1 | 49 | RoW | IMC-002 | ImmuneOncia Therapeutics Inc. | Advanced Cancer | 06/25 | 12/26 | | |
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 740 | Europe, Canada, US, RoW | Dostarlimab | Tesaro, Inc. | Neoplasms | 05/26 | 10/27 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04486664: Effect of Mediterranean Diet in Dyslipidemic Patients |
|
|
| Recruiting | N/A | 100 | RoW | Mediterranean Diet | Gangnam Severance Hospital | Dyslipidemias | 10/20 | 04/21 | | |
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer |
|
|
| Approved for marketing | N/A | | Europe, Canada, RoW | Abemaciclib, LY2835219 | Eli Lilly and Company | Metastatic Breast Cancer | | | | |
NCT06712108: Observational Study of Double Cord Blood Transplant |
|
|
| Recruiting | N/A | 40 | RoW | tranplant | Seoul National University Hospital | Adult Double Unit Cord Blood Transplant | 03/30 | 03/30 | | |
NCT05735418: The Effect of GI Biome #7 on Gut Microbiome and Health of the Elderly |
|
|
| Completed | N/A | 60 | RoW | GI Biome #7, Placebo | Seoul National University Hospital, GI Biome | Muscle Weakness | 04/23 | 12/23 | | |
| Recruiting | N/A | 1000 | Europe, Canada, US, RoW | outcome measures for CIPN testing | University of Milano Bicocca | Chemotherapy-induced Peripheral Neuropathy, Quality of Life | 05/24 | 10/25 | | |
| Rautenberg, Beate |
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Completed | 4 | 89 | Europe | Trabectidin (Yondelis) | North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar | Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma | 08/23 | 08/23 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Kim, Pum-Joon |
| Active, not recruiting | N/A | 2000 | RoW | Xience Sierra stent | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease, Coronary Disease | 08/24 | 12/28 | | |
| Recruiting | N/A | 2000 | RoW | Ultimaster™ Tansei™ stents | Duk-Woo Park, MD, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 12/26 | 12/30 | | |
| Recruiting | N/A | 1000 | RoW | DESyne X2 | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Stenosis, Coronary Occlusion, Coronary Disease | 12/26 | 12/30 | | |
| Recruiting | N/A | 1000 | RoW | BIOFREEDOM™ FAMILY stent | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Stenosis | 12/26 | 12/30 | | |
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus |
|
|
| Recruiting | N/A | 4000 | RoW | high-intensity statin arm, low-intensity statin plus ezetimibe | Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation | Pre Diabetes, ASCVD | 12/27 | 12/27 | | |
| Lee, Bo-In |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease | 01/26 | 01/26 | | |
| In, Yong |
| Active, not recruiting | 3 | 104 | RoW | Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery | Biosolution Co., Ltd. | Articular Cartilage Defect, Articular Cartilage Degeneration | 09/23 | 09/24 | | |
NCT04427930: Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial |
|
|
| Active, not recruiting | 3 | 129 | RoW | JOINTSTEM | R-Bio | Knee Osteoarthritis | 12/26 | 12/27 | | |
NCT04506580: Comparison of Postoperative Wound Between Dermabond Prineo(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and Subcuticular Suture in Simultaneous Total Knee Arthroplasty |
|
|
| Active, not recruiting | N/A | 50 | RoW | DERMABONDâ„¢ PRINEOâ„¢(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture | The Catholic University of Korea | Osteoarthritis, Knee Cutaneous Suture, Dermabond, Subcuticular Suture | 07/20 | 07/20 | | |
NCT04181528: A Comparison of Anatomically Aligned Versus Conventional in Unilateral Total Knee Arthroplasty |
|
|
| Not yet recruiting | N/A | 100 | NA | Total knee arthroplasty implant | The Catholic University of Korea | Knee Osteoarthritis, Anatomically Aligned Total Knee Arthroplasty | 12/20 | 12/22 | | |
NCT04718649: Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 216 | RoW | Celebrex with Joins or not | The Catholic University of Korea, SK Chemicals Co., Ltd. | Osteoarthritis | 12/22 | 12/22 | | |
NCT04684160: Comparison of Joint Awareness Between Fixed-bearing and Mobile-bearing Total Knee Arthroplasty Using Titanium-nitride Coated Posterior-stabilized Prostheses |
|
|
| Active, not recruiting | N/A | 100 | RoW | Fixed-bearing TKA, Mobile-bearing TKA | The Catholic University of Korea | Osteoarthritis, Knee, Arthropathy of Knee, Joint Awareness | 12/22 | 12/22 | | |
NCT05254652: The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients After Total Knee Arthroplasty |
|
|
| Not yet recruiting | N/A | 90 | RoW | Duloxetine 30mg, Cymbalta 30mg, Pregabalin 150mg, Lyrica 150mg | The Catholic University of Korea | Osteoarthritis | 05/23 | 05/23 | | |
NCT05322681: The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty |
|
|
| Not yet recruiting | N/A | 90 | RoW | Pregabalin 150mg, Lyrica 150mg | The Catholic University of Korea | Osteoarthritis | 05/23 | 05/23 | | |
NCT04687462: Comparison of Polyethylene Insert Variances of Different Total Knee Arthroplasty System in the Same Patients |
|
|
| Not yet recruiting | N/A | 50 | NA | 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec) | The Catholic University of Korea | Total Knee Replacement Arthroplasty | 12/23 | 12/23 | | |
| Teixeira, Luis A |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
| Recruiting | N/A | 500 | Europe | Data collection | Assistance Publique - Hôpitaux de Paris | Solid Tumor, Hematologic Malignancy, Thoracic Cancer, Cancer, Treatment-Related, Vaccine Response Impaired | 02/24 | 02/24 | | |
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. |
|
|
| Recruiting | N/A | 120 | Europe | Main study:, Sub-study: | Institut Claudius Regaud, Artios Pharma Ltd | Breast Cancer | 01/27 | 06/27 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
ICRG0101, NCT04273542: Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening |
|
|
| Active, not recruiting | N/A | 1100 | Europe | liquid biopsy | Centre Jean Perrin, International Cancer Research Group, Institut Max Planck d'optique quantique | Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation | 05/29 | 05/29 | | |
| Mansi, Laura |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer |
|
|
| Recruiting | 3 | 554 | Europe | Olaparib (300 mg BID) | Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca | Endometrial Cancer, P53abn | 06/30 | 12/31 | | |
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery |
|
|
| Recruiting | 3 | 250 | Europe, Japan | Carboplatin, Paclitaxel | ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission | Ovarian Cancer | 06/27 | 06/28 | | |
| Recruiting | 3 | 538 | Europe, US | cisplatin | The Netherlands Cancer Institute | Ovarian Cancer | 04/25 | 04/26 | | |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 3 | 270 | Europe, Canada, US, RoW | avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex | Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group | Low Grade Serous Ovarian Cancer | 10/28 | 02/31 | | |
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
|
|
| Active, not recruiting | 2 | 270 | Europe | olaparib, durvalumab, tremelimumab | Centre Georges Francois Leclerc, AstraZeneca | Immunotherapy | 08/27 | 08/27 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS |
|
|
| Recruiting | 2 | 77 | Europe | combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone | ARCAGY/ GINECO GROUP | LOCALLY ADVANCED CERVICAL CANCERS | 12/30 | 12/30 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
EXOMA2, NCT04614480: Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine |
|
|
| Recruiting | 2 | 2518 | Europe | Exome analysis | Centre Georges Francois Leclerc | Cancer | 09/25 | 09/29 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
ITHER, NCT02840058: Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 |
|
|
| Recruiting | N/A | 120 | Europe | Biological samples, Anti PD1/PDL1 treatment | Centre Hospitalier Universitaire de Besancon | Cancer | 03/22 | 12/22 | | |
| Recruiting | N/A | 300 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon | Cancer, Elderly, Healthy Aging | 03/22 | 03/23 | | |
| Active, not recruiting | N/A | 50 | Europe | blood samples | Centre Georges Francois Leclerc | Ovarian Cancer | 11/22 | 11/24 | | |
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer |
|
|
| Recruiting | N/A | 327 | Europe, RoW | | ARCAGY/ GINECO GROUP | Ovarian Cancer | 12/24 | 12/24 | | |
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients At the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer |
|
|
| Recruiting | N/A | 268 | Europe | Multidisciplinary assessment, Standard assesment, Observational cohort | Centre Francois Baclesse | Gynecologic Cancer, Remission | 09/27 | 06/28 | | |
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study |
|
|
| Recruiting | N/A | 250 | Europe | | ARCAGY/ GINECO GROUP, Institut Curie | Metastatic Endometrial Cancer | 12/24 | 12/24 | | |
| Lee, JiEun |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05816655: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 202 | RoW | Fulvestrant plus AI plus ribociclib, AI plus ribociclib | Korea University Guro Hospital | Metastatic Breast Cancer | 12/28 | 06/29 | | |
| Recruiting | 1/2 | 106 | US, RoW | ZB716, Borestrant, Palbociclib, Ibrance® | EnhancedBio USA Inc., Zenopharm | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer | 01/23 | 01/24 | | |
| Kim, Bum-joon |
NCT05964257: To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy |
|
|
| Active, not recruiting | 3 | 188 | RoW | Botulinum toxin type A, normal Saline | Huons Biopharma | Benign Masseteric Hypertrophy | 03/24 | 05/25 | | |
| Dzongowski, Peter |
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above |
|
|
| Completed | 3 | 1544 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA investigational vaccine, Placebo | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 03/23 | 04/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above |
|
|
| Active, not recruiting | 3 | 1457 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA investigational vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 04/25 | | |
